News
Doctors are excited because Novo Nordisk’s obesity drug Wegovy was shown to prevent heart attacks in a new trial. But it’s going to be very expensive, according to a new analysis.
Novo Nordisk A/S agreed to buy an experimental blood-pressure medicine from KBP Biosciences for as much as $1.3 billion, extending a string of recent deals to bolster its drug pipeline.
Danish drugmaker Novo Nordisk will invest 864 million reais ($158.2 million) to revamp a plant in Brazil responsible for pumping out a quarter of its insulin production globally, the firm said on ...
U.S. President Joe Biden and Senator Bernie Sanders called on Novo Nordisk and Eli Lilly to reduce the prices of their weight-loss and diabetes drugs, in a jointly authored opinion piece published ...
Novo Nordisk will soon release results from a study that, if successful, could further uncork demand for new obesity medications and demonstrate long-lasting health benefits.
Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1.
See Also: These Three New Markets May Propel Novo Nordisk’s Ozempic To Greater Heights Silva underwent a fat-dissolving procedure and endoscopic sleeve gastroplasty.
New Playground, New Court, New Classroom? Thank Ozempic. Philanthropies with large stakes in weight-loss drugmakers Eli Lilly and Novo Nordisk have surged in value and are now among the biggest in ...
(Reuters) -Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to develop drugs for cardiometabolic diseases, including obesity ...
Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.
Hundreds of Americans have jumped on a multi-state lawsuit alleging that the makers of Ozempic and Mounjaro caused them life-altering injuries. The suit was filed against Novo Nordisk and Eli ...
Diabetes giants Sanofi, Eli Lilly and Novo Nordisk, plus a trio of pharmacy benefit managers will have to face racketeering charges over claims they systematically hiked the price of insulin drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results